Efficacy of Escitalopram in the Treatment of Internet Addiction
The purpose of this study was to determine whether Lexapro (Escitalopram) is safe and effective in treating problematic internet use.
NCT00565422 — Internet Addiction
Status: Completed
http://inclinicaltrials.com/internet-addiction/NCT00565422/
Evaluation of efficacy and safety of H-coil deep transcranial magnetic stimulation 9 week treatment trial for cannabis addiction as assessed by measures of drug intake and craving.
NCT00543036 — Marijuana Abuse
Status: Recruiting
http://inclinicaltrials.com/marijuana-abuse/NCT00543036/
Maintaining Alcohol Abstinence in Alcoholic Patients With Liver Cirrhosis: Efficacy and Safety of Baclofen Administration in a Randomized Double Blind Controlled Study
Intervention to achieve alcohol abstinence represents the most effective treatment for alcoholic patients with liver cirrhosis. However no trials have evaluated the efficacy of anti-craving drugs in these patients because of the concern that these medications might worsen liver disease. Baclofen is effective to reduce alcohol craving improving abstinence in alcohol-dependent patients. It is mainly eliminated by kidney. No hepatic side-effects have been reported in treated patients. The present study investigates the efficacy and safety of baclofen in achieving and maintaining abstinence in alcoholic cirrhotic patients.
NCT00525252 — Liver Cirrhosis, Alcoholic
Status: Completed
http://inclinicaltrials.com/liver-cirrhosis-alcoholic/NCT00525252/
Naltrexone Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction - a Randomised Study
The purpose of this clinical trial is to study the efficacy and safety of naltrexone implants as relapse prevention for patients that are completing treatment for opiate addiction in inpatient (or similarly controlled) settings. Participants volunteer for the study before being released from inpatient treatment, and are randomized to a naltrexone implant group or a waiting-list control for the duration of the first six months following completion of inpatient treatment. Both groups are free to receive treatment as usual (TAU) from the Norwegian healthcare system. After six months, both groups will be offered to have naltrexone implanted for the remaining six months of the study. The hypotheses are that quality of life, depression, opioid use, will be significantly better in the naltrexone group compared to the non at 6-month follow-up. For the last six months of the trial, the investigators hypothesise that choice of naltrexone implant will mainly strengthen positive tendencies or reverse negative trends on the aforementioned variables. The investigators also hypothesize that the implants can prevent death from opioid overdose up to 6 months after commenced treatment.
NCT00521157 — Opiate Dependence
Status: Completed
http://inclinicaltrials.com/opiate-dependence/NCT00521157/
Cannabis and Psychosis. Randomized Clinical Trial: Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
The purpose of the trial is to investigate the effect of specialized treatment of cannabis abuse among young people with psychosis. The specialized treatment consists of manualized individual treatment and group therapy. It will be compared with the standard treatment, which consists of non-specialized, non-manualized treatment. 140 patients will be randomised to one of the two treatments, and the investigator(s) will be blinded to the treatment received.
NCT00484302 — Schizophrenia
Status: Completed
http://inclinicaltrials.com/schizophrenia/NCT00484302/
Evaluating Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
This study will be a randomized, blinded, placebo-controlled two-group clinical trial. The independent variable is treatment assignment (active 4-mg nicotine lozenge vs. matching placebo lozenge), and the dependent variables are all tobacco and ST abstinence at 3 and 6 months. ST users will be randomly assigned to either the 4-mg active nicotine lozenge or matching placebo.
NCT00392379 — Smokeless Tobacco Use
Status: Completed
http://inclinicaltrials.com/smokeless-tobacco-use/NCT00392379/
On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings
The purpose of this study is to examine the efficacy of providing two levels of psychosocial support along with buprenorphine/naloxone (BUP) maintenance to opioid dependent patients receiving their care in an HIV clinical care setting.
NCT00317460 — HIV Infections
Status: Completed
http://inclinicaltrials.com/hiv-infections/NCT00317460/
A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Standard Medical Management or Enhanced Medical Management for Opioid Analgesic Dependence
The purpose of this study is to determine whether treatment outcome for subjects dependent on prescription opioid analgesics can be improved by adding individual drug counseling to the prescription of buprenorphine/naloxone with standard medical management. This will be examined during: a) an initial four-week treatment with taper; b) a 12-week stabilization treatment for those who do not respond successfully to the initial treatment; and c) a long-term follow-up assessment at 1.5 years, 2.5 years, and 3.5 years after treatment.
NCT00316277 — Substance-related Disorders
Status: Completed
http://inclinicaltrials.com/substance-related-disorders/NCT00316277/
A CTSC Clinical Research Center Study: A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
Characterize the relative abuse liability of a short versus a long acting opioid in chronic pain patients.
NCT00314340 — Chronic Pain
Status: Completed
http://inclinicaltrials.com/chronic-pain/NCT00314340/
Cholesterol and Fatty Acids in Cocaine Addiction Relapse
Many substance dependent individuals continue to abuse a variety of substances during treatment for their disorder. Often, substance dependent individuals are co-diagnosed with depression and violence problems. Supplements of n-3 polyunsaturated fatty acids (PUFAs) may play a role in treating individuals with such substance abuse problems. The purpose of this study is to evaluate the effectiveness of the n-3 PUFAs eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA) in treating relapse, aggression, and depression in substance dependent individuals.
NCT00312455 — Substance-related Disorders
Status: Completed
http://inclinicaltrials.com/substance-related-disorders/NCT00312455/